<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Four-hundred and fifty nine <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients were skin tested with extracts from five lymphoid cell lines </plain></SENT>
<SENT sid="1" pm="."><plain>More than 50% of patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> had positive skin tests with the extracts prepared from the cell line derived from Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and more than 50% of nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> (NPC) patients reacted to the NPC-derived cell line extracts </plain></SENT>
<SENT sid="2" pm="."><plain>Although the significant association between patient diagnosis and orgin of cell lines suggested that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated antigens were responsible for the pattern of delayed hypersensitivity, problems in standardization of antigen potency and non-specificity need to be resolved before this in vivo assay achieves its full potential </plain></SENT>
</text></document>